Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-Of-HEARTs
NCT05616260Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetazolamide in obstructive sleep apnea (OSA) (2 arms), sponsored by University of California, San Diego. Primary endpoints: Apnea Hypopnea Index at 14 days and 24-hour Mean Blood Pressure at 14 days. Started Dec 2022; status: completed.
02
Drugs
acetazolamide
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05616260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616260.